17.07.2017
EU Horizon 2020 Seal of Excellence
Regenics AS, Oslo, Norway, awarded with Horizon 2020 ‘Seal of Excellence’
19.06.2017
Regenics joins consortium for biological drug development receiving 16 mill SEK from Vinnova
Regenics Norway joins international consortium funded by 16 mill SEK from Vinnova, Sweden
15.03.2017
Product agreement with Farmona
Regenics has today agreed with Farmona (PL) a test production of various formulations of its biomarine cosmetic ingredient LEX.  
12.03.2017
More US news coverage of Sapelo Skin care with LEX®
Sapelo Skin Care LEX cosmetics recieves more US press
01.02.2017
Sapelo Skin Care US takes LEX® salmon roe extract to Hollywood
Sapelo Skin Care's new Salmon roe Spring Tide Serum is reported by the Hollywood Reporter as one of the new Luxe Skin Care Products, in company with diamond dust, 24-karat gold,...
11.01.2017
Additional EPO patent granted
The European Patent Office has issued an additional new patent covering Regenics AS proprietary technology. The patent was granted on November 2, 2016 as Patent Number EP 2296676. The patent expires May 7th,...
03.01.2017
New office location in Oslo
Karvesvingen 2, 0579, Oslo, Norway.   
19.12.2016
Gaselle bedrift 2016
Regenics AS one of Norways best performing companies 2016. Out of 264.000 registered businesess i Norway, 2481 companies (0.93 % of all) was selected in 2016 as "Gaselle" (gazelles) based on...
12.10.2016
Regenics launch of new website
New website October 12th 2016!
06.10.2016
Regenics attends BioMarine Business Convention in Oslo, Norway, October 19-21 2016
  BioMarine 2016 will focus on demonstrating the utility and feasibility of achieving a ‘full circle’ of the blue industry value chain. Extracting the ingredients and marine compounds produced during each...
09.09.2016
3D printing Agreement with Chalmers, Sweden
Regenics AS, Norway enter into an agreement with Chalmers, Sweden  on exploring Vernex™ for 3D bioprinting.
09.09.2016
DnB NXT October 19th, 2016 Oslo Innovation Week
Regenics AS presents at DnB NXT October 19th 2016
29.08.2016
Succesfull placement of share issue August 2016
Regenics announces the succesfull private placement of new shares.
18.08.2016
DnB Healtcare conference 2016
Regenics presented at DnB Healtcare conference 2016
18.08.2016
Regenics publish data on vehicle for Vernex® at Drug Delivery meeting, France
Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing, 4th Congress of Drug Delivery, France. September 25-28, 2016
17.08.2016
Regenics in press - Presentation in GENIALT from the Norwegian Biotechnology council
Press: The Norwegian Biotechnology Advisory Board monthly publication, GENIALT, August 2016, focus on Regenics roe technology. 
12.08.2016
Data Protection Officer
Regenics appoints Chief Medical Officer as Data Protection Officer (Personvern ombud).
10.08.2016
Vernex™ Medical device non-binding opinion by SLV
The Norwegian Medicines Agency (SLV) has on August 10th 2016 preliminary reviewed the regulatory status of Vernex™. 
01.08.2016
TGA Sciences, Inc., US provides collagen data for salmon roe extract
Regenics releases salmon roe collagen boosting data in human fibroblasts performed by TGA Sciences, Inc., US.  
27.07.2016
Regenics AS Annual Report 2015
Regenics post a first positive 2015 result with topline in excess of 4 mill NOK. 
11.07.2016
Protocol from Extraordinary Annual Meeting July 11th 2016
July 11th 2016 Protocol from Extraordinary Annual Meeting July 11th 2016
28.06.2016
Canadian National Patent 2016
Canadian National Patent issued to Regenics' technology on June 28, 2016.
27.06.2016
Notice of Extraordinary Annual Meeting July 11th 2016
June 27th 2016 Notice of Annual Meeting July 11th 2016. The Annual Meeting 2016 will tale place at the Companys site Nycovn. 2, Oslo from 3 pm to 5 pm.
22.06.2016
Protocol from Annual Meeting June 22nd 2016
June 22nd 2016 Protocol from Annual Meeting June 22nd 2016

Page 1 of 3   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.